United Kingdom
Spikevax LP.8.1▼ (mRNA-1273.251) 0.1 mg/mL dispersion for injection
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Spikevax LP.8.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The use of this vaccine should be in accordance with JCVI recommendations.
Spikevax JN.1▼ (mRNA-1273.167) dispersion for injection
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Spikevax JN.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The use of this vaccine should be in accordance with licensed recommendations.
Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk. By reporting side effects you can help provide more information on the safety of this medicine.
Contact Moderna
How can we help you?
Report a Side Effect:
UK's MHRA Yellow Card Site or Moderna's Adverse Event Intake Portal
Email Us: WeCare@modernatx.com
Call Us: 0800 085 7562 Monday - Friday 09:00 to 17:00 GMT (closed holidays)
Moderna Biotech Distributor UK Ltd. Registered in England and Wales No. 14200885
Registered Office: 54 Portland Place, London W1B 1DY